Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban for primary prevention of VTE in chemotherapy patients with malignant tumors
ChiCTR2600133390Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of edoxaban in venous thromboembolism (VTE) (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: VTE incidence rate (including DVT and/or PTE). Started Mar 2023; status: completed.
02
Drugs
edoxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2600133390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133390.